# Empirical benchmarking of two recent approaches for augmenting clinical trials via external data PSI 2024, Amsterdam

Erik Hermansson <sup>1</sup> Fredrik Öhrn <sup>3</sup> Stefan Franzén <sup>2</sup> David Svensson <sup>1</sup>

 $^1\mathrm{Respiratory}\ \&\ \mathrm{Immunology}\ \&\ \mathrm{Statistical}\ \mathrm{Innovation},\ \mathrm{AstraZeneca},\ \mathrm{Gothenburg},\ \mathrm{Sweden}$ 

<sup>2</sup>Medical & Payer Evidence Statistics, AstraZeneca, Gothenburg, Sweden

<sup>3</sup>Statistics and Decision Sciences, Global Development, Johnson and Johnson Innovative Medicines, Gothenburg, Sweden

June 4, 2024

# Outline

- Introduction
- Methodology
- Simulation Model
- 4 Large Scale Simulation benchmarking
- 5 Discussion & Conclusion

#### Introduction

#### Bayesian and Frequentist methods

► Two potential ways to do this is Bayesian Dynamic Borrowing (BDB) [1, 6, 8] and Prognostic Score Methodology (PSM) [2, 9], but many more available [8]

## Increased acceptance by regulatory agencies

▶ BDB have been approved by the FDA in some settings where recruitment is difficult and PSM recently went through the process of an EMA qualified opinion [5]

## Setting: Phase 2B with mostly sponsors risk

- One historical trial to borrow from
- ▶ We borrow only the control arm and have a continuous endpoint

#### Robust Mixture Prior

- Many different ways to do Bayesian dynamic borrowing, such as power prior and hierarchical prior [8]. We will focus on Robust Mixture prior (RMP)
  - RMP borrows dynamically via a likelihood weighting. If there is a large prior data conflict the informative prior wont influence the posterior as much [1, 6]
  - ► The borrowing can be expressed as Effective Sample Size (ESS) [4] and can be seen as *expected* additional enrolled control patients
  - ► However, BDB can *potentially* inflate the Type 1 Error and have a lower power.

#### • How to select W?

▶ We choose the weight such that the prior contribute by no more than 50% of the future control arm measured with ESS


# Prognostic Score Methodology

- With relevant historical data one can build a prediction model of the future control response [2, 9] which reduces the residual variance in proportion to the R<sup>2</sup> of the model (and protects the Type 1 Error!)
  - ► This can then be written as an ANCOVA such as  $E[Y_k] = \alpha + \delta T_k + \beta^t x_k + \gamma \hat{z}^{(RCT)}$
  - ► NOTE: For PSM to add value it need to improve the R² above what an ANCOVA would have
- Many different models can be used
  - ► To improve upon an ANCOVA it probably needs to be able to detect potential non-linearity in the data
  - ▶ We have opted for XGBoost as it performs well on tabular data [3]

# Dynamic Twins - A natural conclusion?

- We can combine the two methods by borrowing the control effect after adjusting with PSM. A similar approach have been suggested by Vanderbeek et al [7]
  - ▶ The adjusted control response is the intercept from a linear regression where centered covariates have been included i.e.  $Y = \alpha + \beta(X \bar{X})$  and then  $\mathbf{E}[Y] = \alpha$
- This potentially increases the power by reducing the residual variance and by increasing the effective sample size [4]
  - ► However, we can now have a misspecification of the prognostic model and the future control response!

# Simulation Model




# Simulation set up

- The historical control arm is seen as fixed and the future RCT is simulated from  $y = \delta \cdot T + f_{prog}(\mathbf{x}, b; \mathbf{W}, \mathbf{w}, \mu) + \varepsilon$ 
  - ▶ Three different historical sample sizes, 50, 400 and 1000
  - ▶ The future study has 400 patients and have a 1:1 randomization
- Two different types of prior data conflict
  - By varying μ between -1 and 1, we can create prior data conflict. We call it Locational Conflict.
  - $\blacktriangleright$   $W^2$  is altered between 0 and 2. This is to alter the functional relationship of the future data and is called Functional Conflict.


# Alternative Hypothesis

#### Simulation under H1. 5000 Simulations



# **Null Hypothesis**

#### Simulation under H0. 5000 Simulations



# Discussion & Conclusion

- Both methods are vulnerable to data conflicts, although in different ways.
  - ▶ BDB can have higher type 1 error and lower power
  - While the downside in PSM is limited as the cost is one degree of freedom
  - BDB can be done with only summary level data while PSM requires individual level patient data
- The methods work in different ways to arrive at the same goal higher power/reduced sample size
  - ▶ NB: BDB borrows in absolute numbers while PSM borrows in proportion to the future trial
- When little data is available, PSM does not add much value while BDB can still give meaningful gains.
- One can combine the two methods, but is sensitivity to Locational and Functional Conflict

## References I

- [1] Nicky Best et al. "Assessing efficacy in important subgroup in confirmatory trials: An example using Bayesian dynamic borrowing". In: (2021).
- [2] Carl-Fredrik Burman et al. "Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control data". In: *Pharmaceutical Statistics* n/a (2024), pp. 1–19.
- [3] Léo Grinsztajn, Edouard Oyallon, and Gaël Varoquaux. Why do tree-based models still outperform deep learning on tabular data? 2022.
- [4] Beat Neuenschwander et al. "Predictively consistent prior effective sample sizes". In: *Biometrics* 76.2 (2020), pp. 578–587.
- [5] "Qualification opinion for Prognostic Covariate Adjustment (PROCOVA™)". In: (2022).

## References II

- [6] Heinz Schmidli et al. "Robust meta-analytic-predictive priors in clinical trials with historical control information". In: *Biometrics* 70.4 (2014).
- [7] Alyssa M. Vanderbeek et al. Bayesian Prognostic Covariate Adjustment With Additive Mixture Priors. 2024.
- [8] Kert Viele et al. "Use of historical control data for assessing treatment effects in clinical trials". In: *Pharm Stat* 13 (2014), pp. 41–54.
- [9] David Walsh et al. "Using digital twins to reduce sample sizes while maintaining power and statistical accuracy". In: Alzheimer's & Dementia 17.S9 (2021), e054657.

## Simulation Model

The historical and future control arms are simulated from  $y = f_{prog}(\mathbf{x}, b; \mathbf{w}, \mu) + \varepsilon$  where

$$f_{prog}(\mathbf{x}, b; \mathbf{w}, \mu) = \mu + w_1 \cdot g_1(x_1) + w_2 \cdot g_2(x_2) + w_3 \cdot g_3(x_3) + w_4 \cdot g_4(x_4) + w_5 \cdot g_5(x_5) + w_6 \cdot g_6(x_6, b)$$
(1)

with  $\varepsilon \sim N(0,\sigma)$ , where  $\sigma^2=4$  and  $\sum_{j=1}^6 w_j^2=6$ . The historical data is kept fixed and where the configuration  $\mathbb{W}=1$ ,  $\mathbb{W}=1$  and  $\mu=0$  represents exchangability of the historical and future data. The future RCT is simulated from the following model:

$$y = \delta \cdot T + f_{prog}(\mathbf{x}, b; \mathbf{W}, \mathbf{w}, \mu_1) + \varepsilon, \tag{2}$$

# Learner Comparison

HC.N	Method	Prior Mean R2	Post Mean R2	Drift in R2
HC.N=1000	PSM(LR)	0.33	0.32	0.01
HC.N=1000	PSM(RF)	0.45	0.43	0.02
HC.N=1000	PSM(XG)	0.55	0.54	0.01
HC.N=400	PSM(LR)	0.33	0.31	0.02
HC.N=400	PSM(RF)	0.39	0.38	0.01
HC.N=400	PSM(XG)	0.50	0.49	0.01
HC.N=50	PSM(LR)	0.40	0.25	0.15
HC.N=50	PSM(RF)	0.15	0.18	-0.03
HC.N=50	PSM(XG)	0.26	0.13	0.12

Table: 5000 simulations of the mean  $R^2$  based on in sample predictions and out of sample predictions for different learners and different amount of historical data.

# **Functional Conflict**

